asco.org2 天
About ASCO
Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
asco.org9 天
Conflict of Interest (COI)
The American Society of Clinical Oncology (ASCO) is a professional oncology society committed to conquering cancer through research, education, prevention, and the delivery of high-quality patient ...
asco.org2 天
Current practices and attitudes in menstrual management in adolescents with cancer: A ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org11 天
ASCO Overview
Conquering cancer through research, education, and promotion of the highest quality patient care. ASCO is supported by its affiliate organization, Conquer Cancer, the ASCO Foundation, which funds ...
asco.org2 天
Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Performance of mutation risk prediction models in a racially diverse multi-gene panel ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org2 天
Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...